An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

We report a HER2(T798I) gatekeeper mutation in a patient with HER2(L869R)-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that HER2(L869R) is a neratinib-sensitive, gain-of-function mutation that upon dimerization with mutant HER3(E928G), also present in the...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cancer Discov
Κύριοι συγγραφείς: Hanker, Ariella B., Brewer, Monica Red, Sheehan, Jonathan H., Koch, James P., Sliwoski, Gregory R., Nagy, Rebecca, Lanman, Richard, Berger, Michael F., Hyman, David M., Solit, David B., He, Jie, Miller, Vincent, Cutler, Richard E., Lalani, Alshad S., Cross, Darren, Lovly, Christine M., Meiler, Jens, Arteaga, Carlos L.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2017
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457707/
https://ncbi.nlm.nih.gov/pubmed/28274957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1431
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια